about
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Read More1.1M XNAS Volume
XNAS 16 May, 2025 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Bearish
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..